PTC Therapeutics’ Cancer Stem Cell Program Targeting BMI1 Enters Phase 1 – MarketWatch
|
PTC Therapeutics' Cancer Stem Cell Program Targeting BMI1 Enters Phase 1
MarketWatch "Targeting cancer stem cells by BMI1 inhibition is a promising approach to address the challenge of drug-resistant cancers," stated Lillian Siu, M.D., Princess Margaret Cancer Center, Professor of Oncology, University of Toronto. "Cancer is a complex … |
